Long-term hearing outcomes of children with symptomatic congenital CMV treated with valganciclovir
In: International Journal of Pediatric Otorhinolaryngology, Jg. 118 (2019-03-01), S. 124-127
Online
unknown
Zugriff:
OBJECTIVES: Congenital human cytomegalovirus (cCMV) is a leading cause of pediatric hearing loss. Recent literature has suggested that valganciclovir (VGCV) therapy can improve hearing outcomes. The objective of this study was to evaluate the long-term hearing outcomes among symptomatic CMV patients treated with VGCV. METHODS: A retrospective chart review of symptomatic CMV patients treated with VGCV was completed. The primary endpoint was the change in best ear hearing scores prior to treatment and after follow-up audiograms. A paired-sample t-test was used to evaluate the data. RESULTS: A total of 16 children were included in the study and participants were followed for an average of 3.2 years. There was a measurable worsening, but not a statistically significant change in the best ear hearing scores, where the mean change was 11.9dB (p-value=0.070). However, 14/16 patients (87.5%, p-value
Titel: |
Long-term hearing outcomes of children with symptomatic congenital CMV treated with valganciclovir
|
---|---|
Autor/in / Beteiligte Person: | Sheng, Xiaoming ; Greene, Tom ; Park, Albert H. ; McCrary, Hilary C. |
Link: | |
Zeitschrift: | International Journal of Pediatric Otorhinolaryngology, Jg. 118 (2019-03-01), S. 124-127 |
Veröffentlichung: | Elsevier BV, 2019 |
Medientyp: | unknown |
ISSN: | 0165-5876 (print) |
DOI: | 10.1016/j.ijporl.2018.12.027 |
Schlagwort: |
|
Sonstiges: |
|